Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

ABSTRACT: PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance.See related articles by Lu et al., p. 408, and Tolaney et al., p. 418.

SUBMITTER: Clark AS 

PROVIDER: S-EPMC8278622 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature